The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) has launched on 16 March a strategic roadmap setting out a vision for vaccine research and innovation in Europe. The roadmap will inform strategic decisions on the priorities for future vaccine investment in innovation and technological development at European Union and individual Member State level. Through a bottom-up approach involving all key stakeholders in the European vaccine field, the strategy aims to overcome fragmentation and remove bottlenecks to translation of breakthrough research into innovative vaccines.
‘Will all laboratory animals be retired in 2040?’
Replacing, reducing and refining the use animals in the lab…. Throughout his career Prof. Dr. Coenraad Hendriksen worked on all aspects of the 3Rs, particularly in the vaccine field, and successfully developed variety of alternatives.
With her doctoral research, TU Delft doctoral candidate Ahd Hamidi has made a major contribution to developing an innovative, scalable, affordable version of the Haemophilus influenzae (Hib) vaccine developed by Intravacc. This low-cost vaccine has now been used to protect 200 million children worldwide against Hib diseases such as meningitis, pneumonia, sepsis and otitis media. Hamidi has defended her dissertation at TU Delft on Thursday 3 March.